A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 573 participants.
Also called NCT05514535
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 573 participants
- Sponsor
- Registry
-
NCT05514535 -
2021-004392-13
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Czechia, Greece, Italy, Portugal, Puerto Rico, Romania, Russia, Slovakia, South Africa, Spain, Ukraine
- Registry status
- Completed
Technical summary
Registry record NCT05514535. Randomized; no masking; primary purpose treatment. Start 2022-08-29 (actual); primary completion 2025-03-05 (actual). Results posted on 2026-05-11.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Research Study to Look Into How Semaglutide, Together With a Lower Dose of Insulin Glargine, Compares to a Higher Dose of Insulin Glargine Alone in People With Type 2 Diabetes (SUSTAIN OPTIMIZE)
- Condition
- Diabetes Mellitus, Type 2
- Condition
- Obesity
- Intervention (Drug)
- Semaglutide
- Intervention (Drug)
- Insuline glargine U100 (reduced)
- Intervention (Drug)
- Insuline glargine U100 (titrated)
- Lead sponsor
- Novo Nordisk A/S
Record details
- Record id
cardio:ct-nct05514535- Content hash
7f4dea1c0bd63c0f23e54f3822aa78c27d73285ca46b9383bd79174e1a91898d